-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study

PUBT·06/03/2026 12:01:48
Listen to the news
Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study
  • Medicus submitted a Phase 2b registrational protocol for SkinJect in Gorlin syndrome under its existing FDA IND.
  • Trial targets up to 50 patients; primary endpoint is complete visual clearance in at least 50% of selected lesions at Week 10.
  • FDA orphan drug designation application filed in April; incentives could include waiver of NDA fees above USD 5 million, seven years of exclusivity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.